Cryo-Cell International, Inc. (CCEL)

Over the past six months, Cryo-Cell International's stock (CCEL) has declined by 44.88% over the last 12 months. As of March 27, 2026, the share price was $3.31, down from $6.37 on March 31, 2025, but has increased by 4.41% in the past month. Key events include reporting financial results for fiscal year 2025 with a revenue decrease and a net loss, receiving a NYSE American continued listing notice, reporting fiscal third-quarter 2025 financial results with decreased revenue and net income, providing a dividend update with $3.23 million in cash dividends paid, and initiating a regular quarterly cash dividend of $0.25 per share.

Based on 27 years of historical data, Cryo-Cell International, Inc. exhibits some seasonal patterns with a "Poor" consistency score of 36.9. June has been the strongest month with an average return of 11.20%, while September tends to be the weakest month, averaging a -4.86% return. Overall, 7 out of 12 months typically show positive average returns, with an average annual return of 18.40% and a monthly win rate of 43.5%. For April, the probability of a positive return is 36.36%.

Cryo-Cell International, Inc. (CCEL) specializes in cryopreservation of umbilical cord blood and tissue and was founded in 1989 as the first private cord blood bank in the United States. The company offers private cord blood banking for collection, processing, and storage of umbilical cord blood, which is a source of hematopoietic stem cells. They also provide cord tissue banking for collection and storage of umbilical cord tissue containing mesenchymal stem cells. Cryo-Cell facilitates public cord blood donation, including a partnership with Duke University, and offers adipose tissue cryopreservation for stem cells from fat tissue. The company manufactures the PrepaCyte CB Processing System and provides cold storage services to third-party companies. Cryo-Cell is involved in research and development, including a patented method for processing endometrial stem cells and plans to open infusion clinics.

Cryo-Cell International, Inc. is headquartered in Oldsmar, Florida, United States. The company has a global reach, serving over 500,000 parents from 87 countries, including Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, India, Mexico, Nicaragua, Pakistan, Panama, Peru, Republica Dominicana, and Venezuela.

Cryo-Cell International has a strong reputation as the world's first private cord blood bank, known for high-quality standards and advanced processing technologies. The company's facility is FDA registered, cGMP-/cGTP-compliant, and accredited by AABB and FACT, with ISO 9001:2008 certification. Events affecting its reputation include an active arbitration with Duke University and a NYSE American continued listing notice. Historically, Cryo-Cell has faced legal challenges, including a breach of contract lawsuit and a patent infringement lawsuit, as well as a legal conflict involving breaches of fiduciary duty.

Cryo-Cell International, Inc. (CCEL) has a mix of institutional and individual owners. As of April 6, 2026, there are 19 institutional owners holding a total of 982,906 shares, including Hamilton Lane Advisors Llc, SFI Advisors, LLC, and Vanguard Group Inc. Key individual insider shareholders include Ki Yong Choi, David Portnoy, and George Gaines.